---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040954"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:39:10.567289+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TScan Q2 net loss $24M, cash $208.8M; heme and solid tumor trials advancing

## Summary
- Net loss of $24.0M in Q2 2023, vs $15.1M in Q2 2022; revenue $3.1M (down from $4.1M).
- Ended Q2 2023 with cash $208.8M; raising $134.7M net from June public offering; funded into 2026.
- FDA cleared IND for TSC-200-A0201 (HPV16); third solid tumor IND; three TCR-Ts to enter Phase 1 basket study H2 2023.
- Heme malignancies: TSC-100/101 at dose level 2, no DLTs; expect RP2D and interim data by end of 2023.
- Plans to file INDs for three more TCR-Ts by year-end, including PRAME-targeting TSC-203-A0201.

## SEC filing metadata
- accession: 0000950170-23-040954
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/0000950170-23-040954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/tcrx-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040954
- JSON: https://secwatch.observer/filing/0000950170-23-040954.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040954.txt

## Key facts
- Earnings Releases
  TScan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/0000950170-23-040954-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.